Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.
about
The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.Understanding life and death decisions in human leukaemias.
P2860
Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Treatment of B-cell chronic ly ...... agent and combination therapy.
@en
Treatment of B-cell chronic ly ...... agent and combination therapy.
@nl
type
label
Treatment of B-cell chronic ly ...... agent and combination therapy.
@en
Treatment of B-cell chronic ly ...... agent and combination therapy.
@nl
prefLabel
Treatment of B-cell chronic ly ...... agent and combination therapy.
@en
Treatment of B-cell chronic ly ...... agent and combination therapy.
@nl
P2093
P2860
P356
P1433
P1476
Treatment of B-cell chronic ly ...... agent and combination therapy.
@en
P2093
A Ferrajoli
O Frankfurt
P2860
P2888
P304
P356
10.1038/LEU.2008.322
P577
2008-11-06T00:00:00Z
P5875
P6179
1019940607